Proto-Oncogene Proteins p21(ras)
"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.
| Descriptor ID |
D016283
|
| MeSH Number(s) |
D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
|
| Concept/Terms |
Proto-Oncogene Proteins p21(ras)- Proto-Oncogene Proteins p21(ras)
- p21 c-ras
- c-ras, p21
- p21 c ras
- p21(c-ras)
- ras Proto-Oncogene Protein p21
- ras Proto Oncogene Protein p21
- Proto-Oncogene Proteins c-ras
- Proteins c-ras, Proto-Oncogene
- Proto Oncogene Proteins c ras
- c-ras, Proto-Oncogene Proteins
- Proto-Oncogene Protein ras
- Proto Oncogene Protein ras
- ras, Proto-Oncogene Protein
- ras Proto-Oncogene Product p21
- ras Proto Oncogene Product p21
- c-ras Proteins
- c ras Proteins
- p21(ras)
- Proto-Oncogene Protein p21(ras)
Proto-Oncogene Protein p21(c-Ha-ras)- Proto-Oncogene Protein p21(c-Ha-ras)
- p21 c-Ha-ras
- c-Ha-ras, p21
- p21 c Ha ras
- p21(c-Ha-ras)
- p21 c-H-ras
- c-H-ras, p21
- p21 c H ras
- c-Ha-ras p21
- c Ha ras p21
- p21, c-Ha-ras
Proto-Oncogene Protein p21(c-Ki-ras)- Proto-Oncogene Protein p21(c-Ki-ras)
- p21 c-Ki-ras
- c-Ki-ras, p21
- p21 c Ki ras
- p21(c-Ki-ras)
- p21 c-K-ras
- c-K-ras, p21
- p21 c K ras
- c-Ki-ras p21
- c Ki ras p21
- p21, c-Ki-ras
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".
This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 3 | 4 |
| 2010 | 2 | 6 | 8 |
| 2011 | 2 | 5 | 7 |
| 2012 | 2 | 6 | 8 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 5 | 5 |
| 2015 | 6 | 4 | 10 |
| 2016 | 7 | 1 | 8 |
| 2017 | 3 | 1 | 4 |
| 2018 | 4 | 4 | 8 |
| 2019 | 4 | 2 | 6 |
| 2020 | 2 | 3 | 5 |
| 2021 | 3 | 2 | 5 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.
-
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
-
LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma. Cancer Discov. 2023 04 03; 13(4):1002-1025.
-
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Clin Lung Cancer. 2023 05; 24(3):228-234.
-
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk. J Cancer Res Clin Oncol. 2023 Jul; 149(8):5231-5240.
-
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends Cancer. 2023 01; 9(1):42-54.
-
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood Adv. 2022 10 11; 6(19):5570-5581.
-
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. Clin Lung Cancer. 2022 03; 23(2):e137-e139.
-
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. Lung Cancer. 2021 10; 160:152-165.
-
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021 09; 32(9):1101-1110.
-
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.